Lupus, scleroderma, and rheumatoid arthritis share a common vascular signature: endothelial dysfunction. EECP directly restores endothelial function through pulsatile shear stress — the same mechanism that makes it effective for heart disease.
Each of these conditions involves immune-mediated damage to the endothelium — the single-cell lining of every blood vessel. EECP's mechanism of action directly addresses this shared root cause.
EECP generates rhythmic pulsatile shear stress — the mechanical force that healthy arteries use to maintain endothelial function. In autoimmune disease, this mechanism is particularly relevant because immune-mediated endothelial damage impairs the cell's ability to produce nitric oxide, the primary vasodilator and anti-inflammatory signalling molecule.
EECP restores this signalling cascade: shear stress → eNOS activation → nitric oxide release → vasodilation + anti-inflammatory effect + endothelial progenitor cell mobilization. The result is improved microvascular perfusion, reduced vascular inflammation, and repair of the damaged endothelial lining.
"Endothelial dysfunction is present in the majority of patients with systemic lupus erythematosus and correlates with disease activity and cardiovascular risk. Therapies that restore endothelial function represent a rational approach to reducing vascular complications." — Lupus vascular research literature
Free Patient Guide
8 modules covering what EECP is, who it helps, how to find the right provider, and what to expect — including a section on EECP for autoimmune vascular conditions.